Yvonne Diaz, 55, was diagnosed with stage 4 ALK-positive lung cancer in August 2021. She works in Communications and lives in Holland Park, London with her husband and twin sons, aged 17.
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small…
Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.
A calorie deficit occurs when you burn more calories than you consume, says senior clinical dietitian Jessica Tilton. Here, she explains how physical activity and…
Here we present a visual abstract of a retrospective study by Decaux et al. which evaluated real-world outcomes following at least one dose of Isa-Pd…
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma.
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
The Paris System for Reporting Urinary Cytology (TPS) requires at least 5–10 malignant cells to diagnose HGUC in lower and upper urinary tract specimens, respectively,…
Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
